Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-0.15Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 4.90%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial recovery for ImmuCell Corporation with significant sales growth, improved margins, and a positive EBITDA turnaround. However, historical production challenges and regulatory delays for the Re-Tain product were notable concerns. Overall, while there are areas needing improvement, the company's financial performance and strategic initiatives were largely positive.Company Guidance
During the call, ImmuCell Corporation reported significant improvements in its financial performance for the fourth quarter and the year ended December 31, 2024. The company achieved a 52% sales growth for both the quarter and the full year compared to the previous year, driven by overcoming earlier production challenges. Sales reached $7.8 million in the fourth quarter, suggesting an annual production capacity of $30 million or more. The gross margin improved to 36.5% in Q4, up from previous periods affected by contamination issues, with an aim to exceed 40%. EBITDA swung positively to $1.3 million in Q4 from negative $311,000 in the prior year, and $1.1 million for the year from negative $2.6 million in 2023, marking an improvement of $3.7 million. The company raised $4.4 million through an at-the-market offering, enhancing its cash position to $3.8 million by year-end. Additionally, ImmuCell is advancing its Re-Tain product towards FDA approval, with strategic options under consideration to offset development costs.Significant Sales Growth
ImmuCell Corporation reported a 52% sales growth during both the fourth quarter of 2024 and the full year 2024 compared to the previous year, achieving $7.8 million in sales during the fourth quarter.
Increase in Gross Margin
Gross margin increased by 125% to $2.8 million in Q4 2024 compared to Q4 2023, and by 105% to $7.9 million for the year ended December 31, 2024, compared to 2023.
Positive EBITDA Turnaround
The company generated EBITDA of $1.3 million in Q4 2024 compared to negative EBITDA of $311,000 in Q4 2023, marking a positive swing of approximately $3.7 million for the year.
Improved Cash Position
The company raised net proceeds of almost $4.4 million through at-the-market offering, improving its cash position to $3.8 million as of December 31, 2024, from $979,000 at the end of 2023.
Re-Tain Product Development
ImmuCell is poised to revolutionize subclinical mastitis treatment with Re-Tain, pending FDA clearance for a controlled launch, following significant investment and development.
---
ICCC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ICCC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $5.10 | $5.48 | +7.45% |
| Nov 13, 2024 | $3.53 | $3.60 | +1.98% |
| Aug 13, 2024 | $3.76 | $3.60 | -4.26% |
| May 14, 2024 | $5.48 | $4.88 | -10.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Immucell Corp. (ICCC) report earnings?
Immucell Corp. (ICCC) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Immucell Corp. (ICCC) earnings time?
Immucell Corp. (ICCC) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCC EPS forecast?
Currently, no data Available
---